9th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Zydus Lifesciences receives US FDA approval for Generic hypertension drug

The Ahmedabad-based drugmaker received approval from the US regulatory authority to market Bisoprolol Fumarate and Hydrochlorothiazide tablets in multiple strengths indicated to treat Hypertension.

Birla Sun Life and Nippon Life initiates talks to merge life insurance JVs

According to some sources, Aditya Birla Capital is in discussion to merge Birla Sun Life Insurance venture with Nippon Life, which is a 49 percent partner in Reliance Nippon Life Insurance Company (RNLIC).

Lupin receives US regulatory approval to market generic antibiotic drug in the US

In a statement, the firm stated that it has received tentative approval from the US FDA for its ANDA (Abbreviated New Drug Application) to market the Doxycycline Capsules (40mg) in the American market.

Aurobindo Pharma recall products in the US market over manufacturing issues

According to the latest enforcement report by the US FDA, Aurobindo Pharma USA, Inc is recalling 9,504 bottles of Quinapril and Hydrochlorothiazide tablets due to Current Good Manufacturing Practices (CGMP) deviations.

Piramal Pharma Consumer Products Division launches D2C platform Wellify.in

Drugmaker Piramal Pharma’s Consumer Products Division (CPD) has announced the launch of its D2C Platform, Wellify.in which is a one-stop shop for all the health and wellness brand offerings by the company.

Sun Pharma's Mohali facility receives OAI status from USFDA

The company announced that they have received an OAI (Official Action Indicated) classification from the USFDA, this can affect the approvals pending for other products but it won’t affect the current business from the facility.

Beximco Pharmaceuticals revenue hikes followed by increased domestic sales

The Dhaka-based API (Active Pharmaceutical Ingredient) and Generic drugs manufacturing company declared that the Annual revenue climbed 18% to BDT34.67 Billion from BDT29.49 Billion, with the domestic sales increasing by 21% and export sales by 14%.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?